Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 2
1977 2
1984 7
1985 8
1986 4
1987 4
1988 2
1989 7
1990 1
1991 5
1992 3
1993 3
1994 3
1996 4
1997 2
1998 8
1999 5
2000 1
2001 5
2002 4
2003 4
2004 5
2005 5
2006 3
2007 6
2008 4
2009 4
2010 6
2011 3
2012 10
2013 6
2014 9
2015 6
2016 8
2017 11
2018 11
2019 5
2020 11
2021 5
2022 10
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Among authors: giladi m. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
Massive splenomegaly.
Giladi M, Hennrick K, Shepshelovich D. Giladi M, et al. Eur J Intern Med. 2023 Aug;114:124-125. doi: 10.1016/j.ejim.2023.04.031. Epub 2023 May 2. Eur J Intern Med. 2023. PMID: 37137780 No abstract available.
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, Zeevi E, Munster M, Blat R, Tempel Brami C, Cahal S, Itzhaki A, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y. Voloshin T, et al. Among authors: giladi m. Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. doi: 10.1007/s00262-020-02534-7. Epub 2020 Mar 6. Cancer Immunol Immunother. 2020. PMID: 32144446 Free PMC article.
Cat-scratch disease-associated arthropathy.
Giladi M, Maman E, Paran D, Bickels J, Comaneshter D, Avidor B, Varon-Graidy M, Ephros M, Wientroub S. Giladi M, et al. Arthritis Rheum. 2005 Nov;52(11):3611-7. doi: 10.1002/art.21411. Arthritis Rheum. 2005. PMID: 16255053 Free article.
220 results